Target intelligence / Profile preview

Ras association domain family member 6 (RASSF6)

Target
RASSF6
Molecular classification
Other (Adaptor/scaffold protein), Tumor suppressor protein
01

Overview

Ras association domain family member 6 (RASSF6) is a tumor suppressor protein belonging to the RASSF (Ras association domain family) family. It contains Ras Association (RA) and SARAH (Salvador/RASSF/Hippo) domains and uniquely features a PDZ-binding motif. RASSF6 is frequently silenced by epigenetic mechanisms in various human cancers and functions as a regulator of apoptosis and cell cycle arrest. Mechanistically, RASSF6 stabilizes p53 by blocking MDM2-mediated degradation but can also induce cell cycle arrest and apoptosis independently of p53, in part by modulating the retinoblastoma protein (pRb) and E2F1 axis. RASSF6 interacts with components of the Hippo pathway and modulates their activity, linking this pathway to tumor suppression. Loss or downregulation of RASSF6 is associated with poor prognosis and increased tumor aggressiveness, supporting its function as a tumor suppressor[1][2][4].

Other names
Ras association domain-containing protein 6RASSF6ras association domain-containing protein 6Ras association (RalGDS/AF-6) domain family 6Ras association (RalGDS/AF-6) domain family member 6putative RAS binding protein
02

Mechanism of action

no direct pharmacological modulators; potential action would be restoration of tumor suppressor activity, inhibition of silencing, or upregulation to induce apoptosis in cancer cells

03

Biological functions

ApoptosisCell cycle regulationTumor suppressionInteraction with Hippo pathwayRegulation of p53 and pRb pathways
04

Disease associations

Cancer (tumor suppressor function in various malignancies, including acute lymphocytic leukemia, chronic lymphocytic leukemia, neuroblastoma, metastatic melanoma, gastric cardia adenocarcinoma, gastric cancer, pancreatic ductal adenocarcinoma)
05

Safety considerations

no specific clinical safety concerns reported; potential for off-target effects if targeted therapies are developed
06

Biomarkers

Low/absent expression of RASSF6 as a biomarker for poor prognosis in several cancers (e.g., gastric cancer, leukemia)

Beyond the preview

Go deeper on Ras association domain family member 6 (RASSF6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras association domain family member 6 (RASSF6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call